Humana (NYSE:HUM) Price Target Raised to $300.00 at Robert W. Baird

Humana (NYSE:HUM) had its target price raised by investment analysts at Robert W. Baird from $270.00 to $300.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the insurance provider’s stock. Robert W. Baird’s target price suggests a potential upside of 5.09% from the stock’s current price.

Several other equities analysts also recently weighed in on HUM. JPMorgan Chase & Co. dropped their price objective on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research note on Tuesday, February 18th. Guggenheim started coverage on Humana in a research note on Wednesday, April 9th. They set a “buy” rating and a $326.00 price target for the company. StockNews.com raised shares of Humana from a “hold” rating to a “buy” rating in a research note on Monday, April 7th. Royal Bank of Canada restated an “outperform” rating and set a $283.00 target price on shares of Humana in a report on Wednesday, February 12th. Finally, Barclays upped their price target on shares of Humana from $270.00 to $322.00 and gave the company an “equal weight” rating in a report on Friday, April 11th. Seventeen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $284.90.

Humana Price Performance

Humana stock opened at $285.48 on Tuesday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. Humana has a one year low of $213.31 and a one year high of $406.46. The company has a market cap of $34.46 billion, a P/E ratio of 28.69, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62. The business has a fifty day moving average of $265.80 and a two-hundred day moving average of $270.33.

Humana (NYSE:HUM) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, analysts predict that Humana will post 16.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Humana

A number of large investors have recently bought and sold shares of HUM. Dodge & Cox increased its holdings in shares of Humana by 106.7% during the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock worth $2,587,345,000 after buying an additional 5,264,045 shares during the last quarter. Vanguard Group Inc. increased its stake in Humana by 15.8% during the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock worth $3,254,899,000 after acquiring an additional 1,751,857 shares during the last quarter. Norges Bank purchased a new position in shares of Humana in the 4th quarter worth about $416,202,000. Pzena Investment Management LLC raised its holdings in shares of Humana by 44.0% in the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock worth $915,736,000 after purchasing an additional 1,103,132 shares during the period. Finally, Boston Partners lifted its stake in shares of Humana by 435.8% in the 4th quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock valued at $279,236,000 after purchasing an additional 893,637 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.